

## **BIOTECHNOLOGY POLICY AND THE LAW (599:B10 - CAULFIELD)**

COURSE OUTLINE, 2006

Timothy Caulfield, 461 Law Centre, Phone: 492-8358

[tcaulfld@law.ualberta.ca](mailto:tcaulfld@law.ualberta.ca)

### **DATE**

January 11	Introduction and overview of class goals
January 18	Human reproductive cloning: Examining the social concerns and the role of the law
January 25	Cloning laws and policies: National and international positions and laws
February 1	Stem cell research: laws, policies and social controversies
February 8	Biotechnology patents: human genetics, stem cells and higher life forms
February 15	No class
February 23	Reading week (No Class)
March 1	Biotechnology patents: human genetics, stem cells and higher life forms (class presentation #1)
March 8	Human genetic research, biobanks and genetic therapies (class presentation #2)
March 15	Nanotechnology, Ethics, Law and Society - Lori Sheremeta, Research Associate, University of Alberta and National Institute for Nanotechnology
March 22	Pharmacogenetics: genes, "race" and individually tailored drugs (class presentation #3)
March 29	Emerging regulation issues and policy responses (class presentation #4)
April 5	Nutrigenomics: Genohype or Genohealthy? - Nola Ries, Research Associated, University of Alberta and University of Victoria
April 12	Paper Due

### **COURSE ASSESSMENT**

The final mark will be based on the evaluation of the paper (80%) and the group presentation of a current event (20%). The paper topic must be approved by me in advance. The paper must be submitted no later than **4:00 PM, Wednesday, April 12, 2005**. It should be no more than 25, double spaced, pages. All footnotes should follow the *Canadian Guide to Uniform Legal Citation*. Marks will be deducted for a late submission.

### **GROUP “CURRENT EVENT” PRESENTATION**

The group presentation should be on an emerging health law policy issue. For example, you could select a topic covered in the media, a new case or in a policy report. The presentation should cover the following:

- A description of the issue;
- Why it is a challenging health policy issue; and
- Possible solutions to the policy issue (you don't need to advocate a single policy position).

The presentation will be evaluated on style, organization, knowledge of the issue and the clarity of the policy analysis. Everyone in the group will get the same mark. The presentations will be limited to 20 minutes with 10-20 minutes of questions.

### **CLASS PARTICIPATION**

It is my hope that there will be a lot of discussion during the class. Though I do not assign a specific mark to class participation, I do consider participation when marking the paper.